T6580
Triflusal
≥98% (HPLC), powder
别名:
Triflusal, α,α,α-trifluoro-2,4-cresotic acid acetate, 2-(Acetyloxy)-4-(trifluoromethyl)benzoic acid, Drisgen, acetyl-4-trifluoromethylsalicylic acid
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
white to off-white
溶解性
DMSO: >30 mg/mL
创始人
Uriach
储存温度
2-8°C
SMILES字符串
FC(F)(F)c1cc(c(cc1)C(=O)O)OC(=O)C
InChI
1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)
InChI key
RMWVZGDJPAKBDE-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
相关类别
生化/生理作用
Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action.
Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action. It is an irreversible inhibitor of COX-1 inhibiting thromboxane A2, preventing aggregation; it preserves vascular prostacyclin, thus promoting anti-aggregant effect. Triflusal blocks phosphodiesterase leading to an increase in cAMP levels promoting anti-aggregant effect due to inhibition of calcium mobilization.
特点和优势
This compound was developed by Uriach. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
警示用语：
Warning
危险分类
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
靶器官
Respiratory system
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
法规信息
新产品
此项目有
历史批次信息供参考:
分析证书(COA)
Lot/Batch Number
Ramón Bover et al.
Revista espanola de cardiologia, 62(9), 992-1000 (2009-08-29)
In the NASPEAF (National Study for Prevention of Embolism in Atrial Fibrillation) trial, combination therapy with an anticoagulant and an antiplatelet was more effective than anticoagulation alone in patients with atrial fibrillation. We report long-term follow-up in these patients, including
Rosa M Antonijoan et al.
European journal of clinical pharmacology, 67(7), 663-669 (2011-02-18)
Triflusal is an antiplatelet agent that irreversibly acetylates cyclooxygenase isoform 1 (COX-1) and therefore inhibits thromboxane biosynthesis. It was initially marketed as capsules containing 300 mg of active substance. In 2006 a new 600 mg (10 ml) oral solution form of triflusal was
Jung-Won Suh et al.
International heart journal, 50(6), 701-709 (2009-12-03)
Triflusal is a derivative of acetylsalicylic acid but it exhibits different pharmacological and pharmacokinetic properties. The object of this study was to evaluate the efficacy of additional use of triflusal in patients who underwent drug-eluting stent implantation. First, we prospectively
Carlos R Cámara-Lemarroy et al.
TheScientificWorldJournal, 11, 1886-1892 (2011-11-30)
Ischemia/reperfusion (I/R) is a condition that stimulates an intense inflammatory response. No ideal treatment exists. Triflusal is an antiplatelet salicylate derivative with anti-inflammatory effects. S-adenosylmethionine is a metabolic precursor for glutathione, an endogenous antioxidant. Dextromethorphan is a low-affinity N-methyl-D-aspartate receptor
Emilio García Quetglas et al.
Arzneimittel-Forschung, 58(6), 283-287 (2008-08-06)
Triflusal (CAS 322-79-2) is an antiplatelet agent related to salicylates used in several European and Latin American countries in the treatment of cardiovascular diseases. The aim of this paper was to evaluate the bioequivalence of triflusal derived from two preparations
商品
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持